Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
15(71%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
4
19%
Ph phase_3
17
81%

Phase Distribution

4

Early Stage

0

Mid Stage

17

Late Stage

Phase Distribution21 total trials
Phase 1Safety & dosage
4(19.0%)
Phase 3Large-scale testing
17(81.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

15

trials recruiting

Total Trials

21

all time

Status Distribution
Active(18)
Completed(3)

Detailed Status

Recruiting14
Not yet recruiting3
Completed3
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
21
Active
15
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (19.0%)
Phase 317 (81.0%)

Trials by Status

not_yet_recruiting314%
active_not_recruiting15%
recruiting1467%
completed314%

Recent Activity

Clinical Trials (21)

Showing 20 of 21 trialsScroll for more
NCT06951698Phase 3

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder

Recruiting
NCT06976216Phase 3

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

Recruiting
NCT07285798Phase 3

A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder

Not Yet Recruiting
NCT07284745Phase 3

A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism

Not Yet Recruiting
NCT06585787Phase 3

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

Recruiting
NCT06976203Phase 3

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

Recruiting
NCT07424404Phase 3

A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively

Recruiting
NCT06126224Phase 3

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

Active Not Recruiting
NCT05980949Phase 3

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

Recruiting
NCT05511363Phase 3

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

Recruiting
NCT06951711Phase 3

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)

Recruiting
NCT06882785Phase 3

A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia

Recruiting
NCT06929273Phase 3

A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

Recruiting
NCT06937229Phase 3

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

Recruiting
NCT07118215Phase 1

A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin

Recruiting
NCT07288567Phase 3

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

Recruiting
NCT07061288Phase 1

A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia

Recruiting
NCT06853171Phase 1

Safety, Tolerability, and Pharmacokinetics of KarXT and Dual-burst Release of Xanomeline With Immediate-release Trospium Chloride in Adolescents With Psychiatric Disorders

Completed
NCT06605950Phase 1

A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Xanomeline With Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity and to Assess the Effect of Omeprazole on the PK of Xanomeline With Trospium Chloride in Healthy Adult Participants

Completed
NCT06947941Phase 3

A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)

Not Yet Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
21